AU2006228413C1 - Treatment of Parkinson's Disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands - Google Patents

Treatment of Parkinson's Disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands Download PDF

Info

Publication number
AU2006228413C1
AU2006228413C1 AU2006228413A AU2006228413A AU2006228413C1 AU 2006228413 C1 AU2006228413 C1 AU 2006228413C1 AU 2006228413 A AU2006228413 A AU 2006228413A AU 2006228413 A AU2006228413 A AU 2006228413A AU 2006228413 C1 AU2006228413 C1 AU 2006228413C1
Authority
AU
Australia
Prior art keywords
group
alkyl
propyl
phenyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006228413A
Other languages
English (en)
Other versions
AU2006228413B2 (en
AU2006228413A1 (en
Inventor
Jeanne-Marie Lecomte
Jean-Charles Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Original Assignee
Bioprojet SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006228413(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet SC filed Critical Bioprojet SC
Publication of AU2006228413A1 publication Critical patent/AU2006228413A1/en
Publication of AU2006228413B2 publication Critical patent/AU2006228413B2/en
Application granted granted Critical
Publication of AU2006228413C1 publication Critical patent/AU2006228413C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006228413A 2005-04-01 2006-03-29 Treatment of Parkinson's Disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands Active AU2006228413C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP05290727.6 2005-04-01
US66861805P 2005-04-06 2005-04-06
US60/668,618 2005-04-06
PCT/IB2006/000739 WO2006103546A2 (en) 2005-04-01 2006-03-30 Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands

Publications (3)

Publication Number Publication Date
AU2006228413A1 AU2006228413A1 (en) 2006-10-05
AU2006228413B2 AU2006228413B2 (en) 2011-09-15
AU2006228413C1 true AU2006228413C1 (en) 2012-02-02

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006228413A Active AU2006228413C1 (en) 2005-04-01 2006-03-29 Treatment of Parkinson's Disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands

Country Status (27)

Country Link
US (1) US8486947B2 (enExample)
EP (2) EP1707203A1 (enExample)
JP (3) JP5546761B2 (enExample)
KR (1) KR101308527B1 (enExample)
CN (1) CN101171009B (enExample)
AU (1) AU2006228413C1 (enExample)
BR (1) BRPI0612216B1 (enExample)
CA (1) CA2603656C (enExample)
CY (1) CY1114636T1 (enExample)
DK (1) DK1863487T4 (enExample)
EA (1) EA016007B1 (enExample)
ES (1) ES2426008T5 (enExample)
HR (1) HRP20130748T4 (enExample)
MA (1) MA29353B1 (enExample)
ME (1) ME01713B (enExample)
MX (1) MX2007012162A (enExample)
NO (1) NO343603B1 (enExample)
NZ (1) NZ561940A (enExample)
PL (1) PL1863487T5 (enExample)
PT (1) PT1863487E (enExample)
RS (1) RS52911B2 (enExample)
SG (1) SG147415A1 (enExample)
SI (1) SI1863487T2 (enExample)
TN (1) TNSN07365A1 (enExample)
UA (1) UA94902C2 (enExample)
WO (1) WO2006103546A2 (enExample)
ZA (1) ZA200708086B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN101472887A (zh) 2006-06-23 2009-07-01 艾博特公司 作为组胺h3受体调节物的环丙胺衍生物
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
NZ574873A (en) 2006-07-25 2012-03-30 Cephalon Inc Pyridazinone derivatives as h3 inhibitors
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
CA2712897A1 (en) 2008-01-30 2009-08-06 Pharmacopeia, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
FR2932479A1 (fr) 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
SG11201502210VA (en) * 2012-10-05 2015-04-29 Vtvx Holdings I Llc Treatment of mild and moderate alzheimer's disease
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20200281522A1 (en) 2019-03-06 2020-09-10 Medtronic Xomed, LLC System and method for improved obstructive sleep apnea diagnostic for implantable devices
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
WO2024201139A1 (en) 2023-03-31 2024-10-03 Bioprojet Pharma Polymorph form of pitolisant hydrochloride
TW202535385A (zh) 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 必托里賽（ｐｉｔｏｌｉｓａｎｔ）之新穎調配物及使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011894A1 (en) * 1993-10-29 1995-05-04 The University Of Toledo Histamine h3-receptor antagonists and therapeutic uses thereof
EP0982300A2 (en) * 1998-07-29 2000-03-01 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
WO2003044059A1 (en) * 2001-11-15 2003-05-30 Ortho-Mcneil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
US20040006120A1 (en) * 2000-08-21 2004-01-08 Yates Stephen L Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
US6855560B1 (en) * 1998-10-07 2005-02-15 Ortho Mcneil Pharmaceutical, Inc. Method of identifying compounds that modulate human histamine H3 receptor
WO2005014579A1 (en) * 2003-07-21 2005-02-17 Astrazeneca Ab Imidazol derivatives of piperdine as histamine antagonists

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
ES2108107T3 (es) 1991-02-27 1997-12-16 Seed Capital Investments Derivados de imidazol que tienen actividad antagonista en el receptor h3 de histamina.
AU671092B2 (en) 1991-12-18 1996-08-15 Schering Corporation Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
EP0619818B1 (en) 1991-12-18 1996-07-10 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
WO1994017058A1 (fr) 1993-01-25 1994-08-04 The Green Cross Corporation Compose d'imidazole
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
WO1995006037A1 (en) 1993-08-27 1995-03-02 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
AU693142B2 (en) 1993-11-15 1998-06-25 Schering Corporation Phenyl-alkyl imidazoles as H3-receptor antagonists
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
CA2222099A1 (en) 1995-05-30 1996-12-05 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
WO1996040126A1 (en) 1995-06-07 1996-12-19 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
PL328369A1 (en) 1996-02-09 1999-01-18 Black James Foundation Ligands of histamin h receptor
JP3925579B2 (ja) 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP1186594B1 (en) * 1999-06-11 2009-08-05 Toyama Chemical Co., Ltd. N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
HK1053110A1 (zh) 2000-08-08 2003-10-10 Ortho-Mcneil Pharmaceutical, Inc. 作為h3受體配體的非咪唑芳氧基烷基胺
WO2002013821A1 (en) 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
EP1373218B9 (en) * 2001-03-29 2008-12-03 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Imidazolyl derivatives useful as histamine h3 receptor ligands
WO2003050099A1 (en) * 2001-12-10 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. Phenylalkynes
JP2006505590A (ja) 2002-10-23 2006-02-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体調節物質としてのフェニルピペリジンおよびフェニルピロリジン
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
WO2005007644A1 (ja) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd ヘテロアリールオキシ含窒素飽和へテロ環誘導体
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011894A1 (en) * 1993-10-29 1995-05-04 The University Of Toledo Histamine h3-receptor antagonists and therapeutic uses thereof
EP0982300A2 (en) * 1998-07-29 2000-03-01 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6855560B1 (en) * 1998-10-07 2005-02-15 Ortho Mcneil Pharmaceutical, Inc. Method of identifying compounds that modulate human histamine H3 receptor
US20040006120A1 (en) * 2000-08-21 2004-01-08 Yates Stephen L Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
WO2003044059A1 (en) * 2001-11-15 2003-05-30 Ortho-Mcneil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
WO2005014579A1 (en) * 2003-07-21 2005-02-17 Astrazeneca Ab Imidazol derivatives of piperdine as histamine antagonists

Also Published As

Publication number Publication date
EP1707203A1 (en) 2006-10-04
AU2006228413B2 (en) 2011-09-15
CA2603656A1 (en) 2006-10-05
JP2014062126A (ja) 2014-04-10
CY1114636T1 (el) 2016-10-05
HRP20130748T1 (en) 2013-10-11
MA29353B1 (fr) 2008-03-03
HRP20130748T4 (hr) 2019-11-15
DK1863487T4 (da) 2019-10-14
WO2006103546A3 (en) 2007-03-01
US20090318433A1 (en) 2009-12-24
CN101171009A (zh) 2008-04-30
BRPI0612216B1 (pt) 2022-04-19
JP5546761B2 (ja) 2014-07-09
UA94902C2 (ru) 2011-06-25
KR20080002904A (ko) 2008-01-04
EP1863487A2 (en) 2007-12-12
EP1863487B1 (en) 2013-05-29
TNSN07365A1 (fr) 2008-12-31
JP2016106142A (ja) 2016-06-16
JP5955872B2 (ja) 2016-07-20
JP2008534572A (ja) 2008-08-28
EA200702135A1 (ru) 2008-04-28
RS52911B2 (sr) 2019-11-29
PL1863487T5 (pl) 2021-08-09
DK1863487T3 (da) 2013-08-12
ME01713B (me) 2014-09-20
SI1863487T1 (sl) 2013-09-30
RS52911B (en) 2014-02-28
KR101308527B1 (ko) 2013-09-17
ZA200708086B (en) 2008-10-29
AU2006228413A1 (en) 2006-10-05
BRPI0612216A2 (pt) 2010-10-26
NO20075086L (no) 2007-12-27
SG147415A1 (en) 2008-11-28
MX2007012162A (es) 2007-11-22
PL1863487T3 (pl) 2014-10-31
EA016007B1 (ru) 2012-01-30
NO343603B1 (no) 2019-04-08
CA2603656C (en) 2015-06-16
CN101171009B (zh) 2012-11-07
SI1863487T2 (sl) 2019-11-29
NZ561940A (en) 2010-06-25
PT1863487E (pt) 2013-08-29
US8486947B2 (en) 2013-07-16
EP1863487B2 (en) 2019-07-17
ES2426008T3 (es) 2013-10-18
WO2006103546A2 (en) 2006-10-05
ES2426008T5 (es) 2020-03-20

Similar Documents

Publication Publication Date Title
JP5955872B2 (ja) 非イミダゾールアルキルアミンヒスタミンｈ３−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療
US7138413B1 (en) Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
US6410792B1 (en) Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
TWI453013B (zh) N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
MXPA05013877A (es) Asociacion de antagonista o agonista inverso del receptor h3 de histamina con anti-psicotico o antidepresivo y su utilizacion para preparar medicamento que prevenie los efectos indeseables de medicamentos psicotropicos.
KR100570374B1 (ko) 5-ｈｔ3 및 신경세포의 니코틴작용성 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물을 이용한 치료방법 및 이 화합물을 함유하는 약학적 조성물
WO2006103537A2 (en) Treatment of epilepsy with non-imidazole alkylamines histamine h3-receptor ligands
HK1181676A (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 SEP 2011.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 SEP 2011

FGA Letters patent sealed or granted (standard patent)